Volume 4, Issue 1, March 2020, Page: 24-30
Hospital Based Epidemiology of Neurodegenerative Disease in Cameroon
Doumbe Jacques, Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Gams Massi Daniel, Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Bobda Ngne Alida, Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Mapoure Yacouba, Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Ntone Felicien, Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Kuate Callixte, Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Njamnshi Alfred, Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Received: Jan. 31, 2020;       Accepted: Mar. 2, 2020;       Published: Mar. 10, 2020
DOI: 10.11648/j.cnn.20200401.15      View  58      Downloads  30
Abstract
Background: The world’s population is aging due to a gradual increase in life expectancy. As a result, age related conditions such as neurodegenerative diseases may increase. No previous studies have been carried out on the epidemiological features of these diseases in our country. Objective: The aim of this study was to determine the global prevalence and proportion of each type of neurodegenerative disease, assessing comorbidities and associated factors. Methods: A cross sectional, retrospective descriptive and analytic study over a 15-year period from 2000 to 2014 in the neurological in and out-patients department of the Yaoundé Central Hospital and the Douala General Hospital was carried out. Medical files of patients served as basis for our recruitment. File with four major diagnoses (Parkinsonism, chorea, amyotrophic lateral sclerosis and dementia), made by neurologists were included. Epidemiological, clinical and paraclinical data were recorded for each patient. Results: A total of 54825 new patients were enrolled in both hospitals over the study period. The prevalence of neurodegenerative diseases was 0.74%. Pakinsonism, Dementia, amyotrophic lateral sclerosis and Chorea accounted for 51%, 41.6%, 5.7% and 3.7% respectively. High blood pressure, diabetes, family history of neurodegenerative diseases and age were the major associated factors. Comorbidities such as high blood pressure, diabetes, tobacco consumption, history of stroke were the most common. Conclusion: Neurodegenerative diseases are present in Yaoundé and Douala. Parkinsonism and dementia are more represented. Comorbidities are frequent in patients with degenerative brain diseases.
Keywords
Epidemiology, Neurodegenerative Diseases, Cameroon
To cite this article
Doumbe Jacques, Gams Massi Daniel, Bobda Ngne Alida, Mapoure Yacouba, Ntone Felicien, Kuate Callixte, Njamnshi Alfred, Hospital Based Epidemiology of Neurodegenerative Disease in Cameroon, Clinical Neurology and Neuroscience. Vol. 4, No. 1, 2020, pp. 24-30. doi: 10.11648/j.cnn.20200401.15
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Nations U. World Population Prospects: The 2012 Revision, Highlights and Advance Tables. New York: United Nations Publications [Internet] [cited 2015 Mar 5]. Available from: http://esa.un.org/undp/wpp/unpp/panel_indicators.htm.
[2]
Cartier-Lacave, Sevin C. Maladies neurodégénératives. Encyclopædia Universalis [en ligne].[consulté le 5 Jan 2015]. Consultable à l' URL: http://www.universalis.fr/encyclopedie/maladies-neurodegeneratives/.
[3]
Cannon JR, Greenamyre JT. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. J Soc Toxicol. 2011 Dec; 124 (2): 225–50.
[4]
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. The Lancet. 2005 Dec; 366 (9503): 2112–7.
[5]
Lekoubou A, Echouffo-Tcheugui JB, Kengne AP. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review. BMC Public Health. 2014; 14: 653.
[6]
Kengne AP, Dzudie A, Dongmo L. Epidemiological features of degenerative brain diseases as they occurred in Yaounde referral hospitals over a 9-year period. Neuroepidemiology. 2006; 27 (4): 208–11.
[7]
Kasiulevičius V, Šapoka V, Filipavičiūtė R. Sample size calculation in epidemiological studies. Gerontologiya. 2006; 7 (4): 225–31.
[8]
Defo BK. Demographic, epidemiological, and health transitions: are they relevant to population health patterns in Africa? Glob Health Action 2014, 7: 22443 - http://dx.doi.org/10.3402/gha.v7.22443.
[9]
Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s Disease in Africa: A Systematic Review of Epidemiologic and Genetic Studies. Mov Disord 2006, 21 (12): 2150-6.
[10]
Dahodwala N, Karlawish J, Siderowf A, Duda JE, Mandell DS. Delayed Parkinson’s Disease Diagnosis among African-Americans: The Role of Reporting of Disability. Neuroepidemiology 2011; 36: 150–4.
[11]
Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. NeuroImage 45 (2009) 1241–52.
[12]
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368–76.
[13]
Khedr EM, Fawi G, Abbas MAA, Mohammed TA, El-Fetoh NA, Al Attar G, Zaki AF. Prevalence of Parkinsonism and Parkinson’s disease in Qena governorate/Egypt: a cross-sectional community-based survey. Neurological Research 2015; 37 (7): 607.
[14]
Okubadejo NU, Ojo OO, Oshinaike OO. Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria. BMC Neurology 2010; 10: 1. doi: 10.1186/1471-2377-10-1.
[15]
George-Carey R, Adeloye D, Chan KY, Paul A, Kolcić I, Campbell H, Rudan I. An estimate of the prevalence of dementia in Africa: A systematic analysis. Jogh 2012; 2 (2). doi: 10.7189/jogh.02.020401.
[16]
Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001; 22 (4): 575-80.
[17]
Jiménez Bonilla JF, Carril Carril JM. Molecular neuroimaging in degenerative dementias. Rev Esp Med Nucl Imagen Mol. 2013; 32 (5): 301–9.
[18]
Olayinka OO, Mbuyi NN. Epidemiology of Dementia among the Elderly in Sub-Saharan Africa. International Journal of Alzheimer’s Disease 2014; ID 195750: 15. http://dx.doi.org/10.1155/2014/195750.
[19]
Touré K, Coumé M, Ndiaye, Ndongo ND, Thiam MH. Risk factors for dementia in a Senegalese elderly population. Afr J NeurolSci. 2009; 28 (1): 1–15.
[20]
Toure K, Coume M, Ndiaye M, Zunzunegui MV, Y Bacher, Diop AG, Ndiaye MM. Risk factors for dementia in a Senegalese elderly population aged 65 years and over. Dement Geriatr Cogn Disord Extra 2012; 2: 160-8.
[21]
Quansah E, Karikari TK. Motor Neuron Diseases in Sub-Saharan Africa: The Need for More Population-Based Studies. BioMed Research International 2015, ID 298409: 9.
[22]
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. The Lancet. 2011; 377 (9769): 942-55.
[23]
Marin B, Kacem I, Diagana M, Boulesteix M, Gouider R, Preux PM, et al. Juvenile and adult-onset ALS/MND among Africans: incidence, phenotype, survival: A review. Amyotroph Lateral Scler. 2012; 13: 276–83.
[24]
Imam I, Ogunniyi A. What is happening to motor neuron disease in Nigeria? Annals of African Medicine 2004; 3 (1): 1-3.
[25]
Lenglet T, Camdessanche JP. Amyotrophic lateral sclerosis or not: Keys for the diagnosis. Rev neurol 173 (2017): 280–7.
[26]
Kandil MR, Tohamy SA, Fattah MA, Ahmed HN, Farwiez HM. Prevalence of chorea, dystonia and athetosis in Assiut, Egypt: a clinical and epidemiological study. Neuroepidemiology 1994; 13 (5): 202-10.
[27]
Walker KG, Wilmshurst JM. An update on the treatment of Sydenham’s chorea: the evidence for established and evolving interventions. Ther Adv Neurol Disord 2010; 3 (5) 301-9.28.
Browse journals by subject